bemarituzumab + docetaxel

**Bemarituzumab + docetaxel** is an investigational combination therapy under clinical development for advanced solid tumors, particularly in cancers with FGFR2b overexpression. Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody engineered to selectively bind and inhibit the activity of the fibroblast growth factor receptor 2b (FGFR2b), thereby blocking ligand-mediated activation (notably FGF7, FGF10, FGF22) and downstream signaling involved in cancer cell proliferation and survival. It is also glycoengineered to enhance antibody-dependent cell-mediated cytotoxicity (ADCC) via improved binding to the Fc gamma RIIIA receptor on natural killer (NK) cells. Docetaxel is a small molecule antineoplastic agent belonging to the taxane family that disrupts microtubule function, inhibiting cell division and leading to cancer cell death. The combination is intended to exploit the complementary mechanisms of targeted blockade by bemarituzumab and anti-mitotic cytotoxicity from docetaxel, aiming for synergistic antitumor effects. This specific combination is being evaluated by Amgen and Five Prime Therapeutics in early-phase clinical studies for indications including advanced or metastatic solid tumors with FGFR2b expression, such as gastric cancer and non-small-cell lung cancer[5][7].